EURO SHOCK at a glance

As the first larger clinical study of its kind, EURO SHOCK is testing a novel intervention procedure aimed at reducing the high mortality associated with cardiogenic shock and alleviating its burden on chronic heart failure.

The core aim of EURO SHOCK is to test the acute early use of an Extracorporeal Membrane Oxygenation Machine (ECMO) to improve the poor outcomes seen in patients with cardiogenic shock.

IMPACT

Since cardiogenic shock results in poor quality of life with frequent hospital admissions, dependence on carers and potential loss of employment, the EURO SHOCK project has important societal impacts through improvements in the health and quality of life for the EU citizen and the global population. It delivers on a number of EU policy objectives, and is rooted in the Horizon 2020 Health Call. The outcomes will also have a number of economic impacts, including reducing the excessive healthcare costs associated with cardiogenic shock. It will also offer commercial opportunities for the SME partner in the EURO SHOCK Consortium and lead to more healthcare professionals being employed at the high-intensity end of the care spectrum.

OBJECTIVES

Testing acute early up-front use of ECMO

Comparing the cost-effectiveness of up-front ECMO to the costs of current standard of care

Assessing whether a system of urgent flagged transfer of unwell patients is practical

EURO SHOCK will particularly focus on at risk and vulnerable sub groups such as the elderly and females as well as patients with multi-morbidity. The results of the study will proactively be used to contribute to standards, guidelines and clinical practices for treatment of patient with cardiogenic shock.